摘要
目的:评价吉非替尼二线治疗晚期肺腺癌的疗效及不良反应。方法:32例晚期肺腺癌应用含铂类方案治疗失败后,口服吉非替尼250mg,1次/日,直至进展。30天后评价疗效及不良反应。结果:32例患者中,完全缓解(CR)1例,部分缓解(PR)18例,有效率(RR)为59.4%,稳定(SD)7例,疾病控制率(DCR)为81.35,进展(PD)6例。中位无疾病进展时间(PFS)7个月,1年生存率为56.3%,中位生存时间(OS)为13个月。不良反应主要为皮疹、腹泻,不影响治疗。结论:吉非替尼治疗晚期肺癌疗效好,不良反应能够耐受。
Objective:To evaluate the efficacy and toxicity of gefitinib as the second-line therapy in the patients with lung adenocarcinoma.Methods:32cases with chemo-refractory were administered gefitinib 250mg orally once a day until disease progression.Tumor response and treatment toxicities were evaluated monthly.Results:Complete regression was seen in one patient.partial response and stable disease were respectively 18and 7patients.The median PFS was 7months.One year survival rate was 56.3%.Median OS was 13 months.The most adverse reactions were mild rash and diarrhea.Conclusion:Gefitinib as the second-line therapy in advanced lung adenocarcinoma is effective.It is well tolerated with adverse reaction.
关键词
吉非替尼
晚期肺腺癌
gefitinib
advanced lung adenocarcinoma